Skip to content
How It Works
Explore
Resources Ask a Question
Who It's For
Patients
Decode results, prep for appointments, weigh options.
Caregivers & advocates
Carry the research load for someone you love.
Providers & clinicians
Resources for patients in your practice.
Log In Ask a Question
PubMed This is a summary of 26 peer-reviewed journal articles Updated
Gynecologic Oncology

Why Rare Ovarian Cancer is Biologically Unique

At a Glance

Rare ovarian cancers, such as low-grade serous and clear cell, are biologically distinct from common ovarian cancer. Specialized pathology testing using specific protein markers like PAX8 and wild-type p53 is essential to secure an accurate diagnosis and the correct treatment plan.

While all ovarian cancers start in the same general area, they are biologically as different as a thunderstorm is from a wildfire. The common type, high-grade serous ovarian cancer (HGSOC), is defined by a “broken” gene called TP53, which causes cells to grow chaotically and aggressively [1][2]. Rare ovarian cancers, however, follow different “instruction manuals” for growth, often relying on specific genetic pathways that can be targeted with specialized treatments [3][4].

The Biology of Rare Subtypes

Understanding the molecular engine driving your cancer helps explain why it behaves differently than the common type.

  • Low-Grade Serous (LGSOC): Unlike the aggressive high-grade version, LGSOC is driven by the MAPK pathway (often through KRAS or BRAF mutations) [3][5]. It usually shows a “wild-type” p53 pattern under a microscope. “Wild-type” simply means the gene looks normal—exactly as it exists in the wild—which is a key way doctors prove it isn’t the common high-grade type [1][6].
  • Clear Cell Carcinoma: This type is frequently linked to endometriosis [7][8]. It is often driven by mutations in ARID1A and PIK3CA, which change how the cell uses energy and repairs itself [9][10].
  • Mucinous Carcinoma: These tumors arise from a specific pathway where cells begin to look and act like the lining of the digestive tract [11]. They often evolve from benign or “borderline” tumors rather than starting as high-grade cancer [12].
  • Sex Cord-Stromal: Adult Granulosa Cell Tumors are almost always driven by a specific mutation in the FOXL2 gene [13]. Other stromal tumors, like Sertoli-Leydig cell tumors, are frequently linked to mutations in the DICER1 gene [14][15].
  • Germ Cell Tumors: These cancers arise from the reproductive cells of the ovary. Biologically, they are prone to producing specific hormones and proteins, making them highly identifiable and exceptionally responsive to chemotherapy [16][17].

The Challenge of Getting the Right Diagnosis

Because rare ovarian cancers are so uncommon, they are sometimes misidentified. Specialized testing is often required to confirm the diagnosis.

Subtype Common Diagnostic Pitfall How Doctors Verify It
Mucinous Often confused with cancer that spread from the appendix or colon [18]. Doctors use markers like CK7 (usually positive in the ovary) and SATB2 (usually positive in the colon) to find the true home of the cancer [19][20].
LGSOC Can be mistaken for High-Grade Serous (HGSOC) if the pathologist is not a specialist. Pathologists look for a normal (“wild-type”) p53 pattern and a low “mitotic rate” (meaning the cells are dividing slowly) [1][6].
Clear Cell Can look like other types under a standard microscope. Specialized markers like HNF-1beta and Napsin A are used to “fingerprint” the cells as clear cell [21][22].

The Role of Pathology Markers (IHC)

To distinguish your cancer, pathologists use Immunohistochemistry (IHC)—a process of using special dyes to see which proteins are present in your cells.

  • PAX8: A “master switch” protein often found in tumors of the female reproductive system. It helps prove a tumor started in the ovary rather than the colon or breast [23][24].
  • CK7 and CK20: These are structural proteins. A result of CK7+ / CK20- strongly suggests the cancer started in the ovary, while the opposite pattern (CK7- / CK20+) usually points to a gastrointestinal origin [25][20].
  • SATB2: This is a highly specific marker for the lower digestive tract. If a “mucinous ovarian tumor” tests positive for SATB2, it is very likely a metastasis from the colon or appendix rather than a primary ovarian cancer [20][26].

Because treatment for colon cancer is vastly different from treatment for ovarian cancer, ensuring these markers are checked is a vital step in your care. To see exactly how to read these results on your own paperwork, proceed to Decoding Your Pathology Report: A Checklist.

Common questions in this guide

What does wild-type p53 mean on my pathology report?
A wild-type p53 result means the gene looks normal under a microscope. Doctors use this normal result to confirm you have a rare subtype like low-grade serous ovarian cancer rather than the more common high-grade type.
How do doctors know my mucinous tumor started in the ovary and not the colon?
Mucinous ovarian tumors can closely resemble cancers that spread from the appendix or colon. Pathologists use special protein stains like CK7 and SATB2 to verify exactly where the tumor originated so you get the correct treatment.
What is the PAX8 marker in ovarian cancer?
PAX8 is a master switch protein frequently found in tumors of the female reproductive system. If your tumor tests positive for PAX8, it helps confirm the cancer started in the ovary rather than in the digestive tract or breast.
Is clear cell ovarian cancer linked to endometriosis?
Yes, clear cell carcinoma is frequently linked to a history of endometriosis. This connection often involves specific genetic mutations, such as ARID1A, which change how the cells use energy and repair themselves.
What is immunohistochemistry (IHC) testing?
Immunohistochemistry is a process where pathologists use special dyes to highlight specific proteins in your cancer cells. The resulting pattern of proteins acts like a fingerprint to identify your exact type of rare ovarian cancer.

Questions to Ask Your Doctor

Curated prompts to bring to your next appointment.

  1. 1.Can you explain the specific immunohistochemistry (IHC) markers used to confirm my diagnosis? Specifically, what were the results for p53, PAX8, and CK7/CK20?
  2. 2.My diagnosis is mucinous—how did the pathology team rule out a primary tumor in my appendix or colon? Was a SATB2 test performed?
  3. 3.Does my pathology report show a 'wild-type' p53 pattern? How does that help distinguish my cancer from the more common high-grade serous type?
  4. 4.Are there specific molecular mutations, like KRAS, BRAF, or ARID1A, that drive my tumor's growth?
  5. 5.Is my cancer linked to an underlying condition like endometriosis, and does that affect my treatment options?

Questions For You

Tap a prompt to share your answer — we'll use it plus this page's context to start a tailored conversation.

References

References (26)
  1. 1

    Serous borderline ovarian tumor and low-grade serous ovarian cancer.

    Sandrasegaran K, Das A, Shah A, et al.

    Abdominal radiology (New York) 2026; (51(3)):1541-1553 doi:10.1007/s00261-025-05143-z.

    PMID: 40748460
  2. 2

    Further Understanding of High-Grade Serous Ovarian Carcinogenesis: Potential Therapeutic Targets.

    Voutsadakis IA

    Cancer management and research 2020; (12()):10423-10437 doi:10.2147/CMAR.S249540.

    PMID: 33116896
  3. 3

    Low-grade serous ovarian carcinoma: A comprehensive literature review.

    Goulding EA, Simcock B, McLachlan J, et al.

    The Australian & New Zealand journal of obstetrics & gynaecology 2020; (60(1)):27-33 doi:10.1111/ajo.13105.

    PMID: 31849044
  4. 4

    Therapeutic advances and molecular insights in low-grade serous ovarian carcinoma.

    Kabirian R, Gaillard T, Bello-Roufai D, et al.

    Bulletin du cancer 2026; (113(4)):533-540 doi:10.1016/j.bulcan.2025.11.005.

    PMID: 41402140
  5. 5

    Innovations in Rare Gynecologic Cancer: Melanoma, Neuroendocrine, and Low-Grade Serous Ovarian.

    Au-Yeung G, MacArthur E, Chan J, et al.

    American Society of Clinical Oncology educational book. American Society of Clinical Oncology. Annual Meeting 2024; (44(3)):e431818 doi:10.1200/EDBK_431818.

    PMID: 39177646
  6. 6

    Low-grade serous carcinoma detected from intraoperative peritoneal washings: Cytological findings and detection of KRAS mutation.

    Yamamoto E, Warigaya K, Kinoshita Y, et al.

    Cancer reports (Hoboken, N.J.) 2022; (5(10)):e1676 doi:10.1002/cnr2.1676.

    PMID: 35801373
  7. 7

    Aggressive Serous Carcinomas of the Female Reproductive Tract: Cancer-Prone Cell States and Genetic Drivers.

    Phuong DJ, Pirtz MG, Ralston CQ, et al.

    Cancers 2025; (17(4)) doi:10.3390/cancers17040604.

    PMID: 40002199
  8. 8

    Disparity in the era of personalized medicine for epithelial ovarian cancer.

    Devlin MJ, Miller RE

    Therapeutic advances in medical oncology 2023; (15()):17588359221148024 doi:10.1177/17588359221148024.

    PMID: 36643655
  9. 9

    The unique metabolome of clear cell ovarian carcinoma.

    Ji JX, Hoang LN, Cochrane DR, et al.

    The Journal of pathology 2024; (264(2)):160-173 doi:10.1002/path.6329.

    PMID: 39096103
  10. 10

    Clinical and pathological associations of PTEN expression in ovarian cancer: a multicentre study from the Ovarian Tumour Tissue Analysis Consortium.

    Martins FC, Couturier DL, Paterson A, et al.

    British journal of cancer 2020; (123(5)):793-802 doi:10.1038/s41416-020-0900-0.

    PMID: 32555365
  11. 11

    The molecular origin and taxonomy of mucinous ovarian carcinoma.

    Cheasley D, Wakefield MJ, Ryland GL, et al.

    Nature communications 2019; (10(1)):3935 doi:10.1038/s41467-019-11862-x.

    PMID: 31477716
  12. 12

    Low grade serous ovarian cancer - A rare disease with increasing therapeutic options.

    Zwimpfer TA, Tal O, Geissler F, et al.

    Cancer treatment reviews 2023; (112()):102497 doi:10.1016/j.ctrv.2022.102497.

    PMID: 36525716
  13. 13

    Genetic and molecular changes in ovarian cancer.

    Hollis RL, Gourley C

    Cancer biology & medicine 2016; (13(2)):236-47 doi:10.20892/j.issn.2095-3941.2016.0024.

    PMID: 27458531
  14. 14

    Recurrent gynandroblastoma of the ovary with germline DICER1 mutation: A case report and review of the literature.

    Mercier AM, Zorn KK, Quick CM, Huffman LB

    Gynecologic oncology reports 2021; (37()):100806 doi:10.1016/j.gore.2021.100806.

    PMID: 34169133
  15. 15

    Practical roles for molecular diagnostic testing in ovarian adult granulosa cell tumour, Sertoli-Leydig cell tumour, microcystic stromal tumour and their mimics.

    Rabban JT, Karnezis AN, Devine WP

    Histopathology 2020; (76(1)):11-24 doi:10.1111/his.13978.

    PMID: 31846522
  16. 16

    Differences in Characteristics and Outcomes Between Large-Cell Neuroendocrine Carcinoma of the Ovary and High-Grade Serous Ovarian Cancer: A Retrospective Observational Cohort Study.

    Pang L, Guo Z

    Frontiers in oncology 2022; (12()):891699 doi:10.3389/fonc.2022.891699.

    PMID: 35600342
  17. 17

    Multidisciplinary management of ovarian germ cell tumours-a single institutional study from India.

    Ganguly S, Gargy S, Basu A, et al.

    Ecancermedicalscience 2021; (15()):1290 doi:10.3332/ecancer.2021.1290.

    PMID: 34824613
  18. 18

    Mucinous Ovarian Carcinoma.

    Morice P, Gouy S, Leary A

    The New England journal of medicine 2019; (380(13)):1256-1266 doi:10.1056/NEJMra1813254.

    PMID: 30917260
  19. 19

    A combination of the immunohistochemical markers CK7 and SATB2 is highly sensitive and specific for distinguishing primary ovarian mucinous tumors from colorectal and appendiceal metastases.

    Meagher NS, Wang L, Rambau PF, et al.

    Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc 2019; (32(12)):1834-1846 doi:10.1038/s41379-019-0302-0.

    PMID: 31239549
  20. 20

    SATB2 as an Immunohistochemical Marker for Colorectal Adenocarcinoma: A Concise Review of Benefits and Pitfalls.

    Berg KB, Schaeffer DF

    Archives of pathology & laboratory medicine 2017; (141(10)):1428-1433 doi:10.5858/arpa.2016-0243-RS.

    PMID: 28968158
  21. 21

    What Is New on Ovarian Carcinoma: Integrated Morphologic and Molecular Analysis Following the New 2020 World Health Organization Classification of Female Genital Tumors.

    De Leo A, Santini D, Ceccarelli C, et al.

    Diagnostics (Basel, Switzerland) 2021; (11(4)) doi:10.3390/diagnostics11040697.

    PMID: 33919741
  22. 22

    [Diagnostic value of combined detection of HNF-1β and Napsin A in the diagnosis of ovarian clear cell carcinoma].

    Wang J, Li Q, Cheng X, et al.

    Zhonghua bing li xue za zhi = Chinese journal of pathology 2015; (44(12)):874-8.

    PMID: 26888504
  23. 23

    Diagnostic roles of PAX8 immunohistochemistry in ovarian tumors.

    Kim J, Kim NY, Pyo JS, et al.

    Pathology, research and practice 2023; (250()):154822 doi:10.1016/j.prp.2023.154822.

    PMID: 37742476
  24. 24

    A combination of immunohistochemical markers, MUC1, MUC5AC, PAX8 and growth pattern for characterization of mucinous neoplasm of the ovary.

    Chelariu-Raicu A, Holley E, Mayr D, et al.

    International journal of gynecological cancer : official journal of the International Gynecological Cancer Society 2022; (32(5)):662-668 doi:10.1136/ijgc-2021-003104.

    PMID: 35185017
  25. 25

    Mucinous Ovarian Tumors.

    Mills AM, Shanes ED

    Surgical pathology clinics 2019; (12(2)):565-585 doi:10.1016/j.path.2019.01.008.

    PMID: 31097115
  26. 26

    Diagnostic Utility of SATB2 in Metastatic Krukenberg Tumors of the Ovary: An Immunohistochemical Study of 70 Cases With Comparison to CDX2, CK7, CK20, Chromogranin, and Synaptophysin.

    Yang C, Sun L, Zhang L, et al.

    The American journal of surgical pathology 2018; (42(2)):160-171 doi:10.1097/PAS.0000000000000951.

    PMID: 28914716

This page explains the biology and pathology of rare ovarian cancers for informational purposes only. Always consult your gynecologic oncologist and pathologist for guidance on interpreting your specific diagnosis and pathology report.

Get notified when new evidence is published on Rare ovarian cancer.

We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.